Pulse of Asia 2022

Speaker's biography and Meeting abstract

Toru Miyoshi, M.D,Ph.D 
Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, 
Dentistry and Pharmaceutical Sciences, 
Okayama, Japan
Dr. Toru Miyoshi has been a Lecturer of Dept. of Cardiovascular Medicine at Okayama University Hospital since 2014. He graduated Okayama University Medical School, Japan and medical license in 1996. He subsequently graduated his residency of cardiology at affiliated hospitals of Okayama University. Then he had studied at the Cardiovascular Research Center at University of Virginia, USA for two years. After that, He obtained the Doctor of Medicine at Okayama University. He is a board-certificated physician of Japanese Cardiology Society, Japanese Society of hypertension, and Japanese atherosclerosis society.

His clinical interests include the diagnosis and treatment of vascular dysfunction, and its disassociation with acute coronary syndrome. He has especially focused on parameters of arterial stiffens. Besides his interest in clinical service, he is a basic researcher in the field of vascular biology. 

Dr. Miyoshi is actively involved in cutting edge research and has published his work in prestigious journals as well as presented his work at several national Cardiology meetings. He is also a fellow of Japanese college of Cardiology and European Society of Cardiology. He published more than 200 manuscripts.

 

Meeting abstract

Lecture title:
A multicenter trial in Japan: CAVI-J
Toru Miyoshi
Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine,
Dentistry and Pharmaceutical Sciences, Okayama, Japan

Aims: A prospective multicenter study was conducted to evaluate the usefulness of the cardioankle vascular index (CAVI) in Japan (CAVI-J), in terms of its utility as a predictor of cardiovascular (CV) events in patients with cardiovascular risks.
Methods: The study included individuals aged between 40 and 74 years with at least one of the risk factors for CV disease. The participants were followed up prospectively for 5 years from the date of the CAVI measurement. The primary outcome was a composite of CV events, including CV-related death, myocardial infarction, and stroke.
Results: The final analysis included 2,938 patients (927 females; mean age, 63 years) with a median follow-up period of 4.9 years. This study included 1,114 (38%) patients with a history of coronary artery disease or cerebral infarction. During the follow-up period, 82 patients experienced primary outcomes including 13 CV deaths, 44 non-fatal strokes, and 25 non-fatal myocardial infarctions. Every 1-point increment in the CAVI was associated with an increased risk of the primary outcomes, after adjusting for confounding factors (hazard ratio, 1.38 [95%
confidence interval, 1.16‒1.65]). This study also determined the incremental value of the CAVI for predicting CV events. The addition of the CAVI to a baseline model that included traditional risk factors significantly increased the global chi-square value from 33.8 to 45.2.
Conclusion: CAVI-J demonstrated that higher CAVI in patients with CV risk factors indicated an elevated risk of CV events. Furthermore, adding the CAVI to a model of clinical risk factors improved the model’s ability to predict the risk of CV events. These data suggest that the CAVI is clinically useful for the assessment of the risk of CV events among patients with CV risk factors.